Menarini will pay Glenmark an undisclosed amount up front plus milestone payments for exclusive rights to market Ryaltris olopatadine/mometasone furoate nasal spray in 33 European countries, Ryaltris developer Glenmark has announced. Glenmark will be continue to be responsible for European development and regulatory approval of the nasal spray for the treatment of seasonal allergic rhinitis.
Ryaltris is currently approved in several countries, including Australia, South Korea, Ukraine, and Uzbekistan. Glenmark said that it plans to launch the product in Ukraine and Uzbekistan within a few months. In Australia, Ryaltris is marketed by Seqirus, and Yuhan is expected to launch the nasal spray in South Korea by the end of the first quarter of 2021. According to Glenmark, Grand Pharmaceutical is expected to submit an IND in China soon. Hikma Pharmaceuticals is set to commercialize Ryaltris in the US, where Glenmark received a complete response letter to its NDA for the nasal spray in 2019.
Glenmark Pharmaceuticals Executive VP, Business Head EMEA-L, Achin Gupta said, “We are excited to partner with Menarini for Ryaltris across Europe as they have a proven track record in partnering and commercializing respiratory products in the region. This partnership is another step in establishing Glenmark’s respiratory focus in Europe. While Glenmark will launch Ryaltris through its own front ends in some markets, this arrangement will allow the product to compete across Europe. This is also aligned with our vision to make Ryaltris the first global brand of Glenmark by launching it in several markets across the world.”
Menarini Group General Manager Pio Mei commented, “We are delighted to have undertaken this exclusive licensing agreement with Glenmark Pharmaceuticals. Ryaltris is a perfect addition to our European respiratory and allergy portfolio and we can count on our established experience in the relevant therapeutic area to bring this novel option to patients. We look forward to receiving Ryaltris registration and being able to launch operations as soon as practicable.”
Read the Glenmark Pharmaceuticals press release.
